MarketPulse

PDUFA

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aicuris Wins FDA Priority Review for First HSV Treatment in 20+ Years

Aicuris receives FDA Priority Review for pritelivir, a novel herpes simplex virus treatment. Phase 3 data shows 82.4% healing rate; PDUFA decision expected Q4 2026.
AHKSYPhase 3 trialPDUFA
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Grace Therapeutics to Present at TD Cowen Conference; FDA Sets GTx-104 Review Date

Grace Therapeutics will present at TD Cowen conference in March 2026. FDA sets April 2026 review date for GTx-104 aneurysmal subarachnoid hemorrhage treatment.
GRCEFDA approvalclinical-stage